ALAMAR BIOSCIENCES INC
ALMRNASDAQTrading Snapshot
- Day Range
- $31.84 – $34.40
- 52-Week Range
- $18.85 – $39.61
- Volume (shares)
- 1,109,129
- Avg Volume (shares)
- —
- Shares Outstanding
- 69.4M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $74M
- Last Q Revenue
- $29M
- P/E Ratio
- -64.7
- P/S Ratio
- 42.9x
- EPS (TTM)
- $-0.59
- Dividend Yield
- 0.00%
ALAMAR BIOSCIENCES INC
ALMRFinancial history unavailable.
StockOtter · stockotter.spaceAbout ALAMAR BIOSCIENCES INC
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Published in Nature Com
Alamar: The Consumables Flywheel Is Just Getting Started
Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merr
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be p